Lantheus (NASDAQ:LNTH) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Lantheus (NASDAQ:LNTH) from a buy rating to a strong-buy rating in a research note released on Saturday morning.

A number of other equities analysts have also commented on the company. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Truist Financial boosted their price target on shares of Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Citizens Jmp upped their price objective on shares of Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 24th. Finally, Mizuho increased their price objective on shares of Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.14.

Lantheus Stock Performance

Shares of Lantheus stock opened at $74.47 on Friday. The stock has a market cap of $4.85 billion, a price-to-earnings ratio of 22.10 and a beta of -0.11. Lantheus has a twelve month low of $47.25 and a twelve month high of $108.91. The company’s fifty day moving average is $72.49 and its 200 day moving average is $63.33. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The business had revenue of $406.79 million during the quarter, compared to analyst estimates of $367.03 million. During the same period last year, the company earned $1.59 EPS. Lantheus’s revenue for the quarter was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts forecast that Lantheus will post 6.01 EPS for the current year.

Institutional Trading of Lantheus

Large investors have recently modified their holdings of the stock. Elevation Point Wealth Partners LLC acquired a new position in shares of Lantheus during the 2nd quarter valued at $26,000. Osterweis Capital Management Inc. acquired a new stake in Lantheus in the second quarter worth $36,000. Hantz Financial Services Inc. increased its stake in Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares in the last quarter. First Horizon Corp bought a new stake in Lantheus in the third quarter valued at $26,000. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.